Work

Out-of-Pocket Cost of Spinal Muscular Atrophy Gene Therapies Among Commercially Insured Patients

Year: 2026

Type: article

Abstract: This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.

Source: Archives of Pediatrics and Adolescent Medicine

DOI: 10.1001/jamapediatrics.2026.0641

Authors: Maria Sckaff, Ilina C. Odouard, Jeromie Ballreich, Gerard Anderson, Mariana P. Socal

Institution: Johns Hopkins University

Language: English

Topic: Neurogenetic and Muscular Disorders Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7154183985

FWCI: 4.102

Cites: 2

Cited by: 1

Related to: